SureTrader
Home > Boards > US Listed > Medical - Drugs > Momenta Pharmaceuticals, Inc. (MNTA)

MOMENTA PHARMACEUTICALS, INC. v. AMPHASTAR PHARMACEUTICALS, INC.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
floblu14 Member Profile
Member Level 
Followed By 18
Posts 2,804
Boards Moderated 0
Alias Born 07/20/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/14/2018 6:33:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/14/2018 6:31:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/14/2018 6:31:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/14/2018 6:30:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/14/2018 6:30:05 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2018 2:31:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2018 10:01:19 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/13/2018 6:10:35 AM
Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL GlobeNewswire Inc. - 2/13/2018 1:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/12/2018 4:42:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/12/2018 4:42:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/12/2018 4:41:13 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/9/2018 2:15:08 PM
Schedule 13g Edgar (US Regulatory) - 2/8/2018 3:15:34 PM
Momenta Pharmaceuticals to Webcast Presentation at the LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire Inc. - 2/8/2018 8:00:00 AM
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast GlobeNewswire Inc. - 2/7/2018 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/1/2018 4:45:31 PM
Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufa... GlobeNewswire Inc. - 1/30/2018 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/19/2018 2:39:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/8/2018 8:01:53 AM
Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal A... GlobeNewswire Inc. - 1/5/2018 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 4:29:27 PM
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept) GlobeNewswire Inc. - 1/3/2018 4:05:00 PM
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept) PR Newswire (US) - 1/3/2018 4:05:00 PM
Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference GlobeNewswire Inc. - 12/28/2017 8:00:00 AM
floblu14 Member Level  Wednesday, 12/07/11 09:36:20 AM
Re: None
Post # of 18243 
MOMENTA PHARMACEUTICALS, INC. v. AMPHASTAR PHARMACEUTICALS, INC.

MOMENTA PHARMACEUTICALS, INC., Plaintiff-Appellee, and
SANDOZ, INC., Plaintiff-Appellee,
v.
AMPHASTAR PHARMACEUTICALS, INC., INTERNATIONAL MEDICATION SYSTEMS, LTD., WATSON PHARMACEUTICALS, INC. and WATSON PHARMA, INC., Defendants-Appellants.

Nos. 2012-1062, 2012-xxxx, 2012-xxxx

United States Court of Appeals, Federal Circuit.


December 6, 2011.


This order is nonprecedential

ORDER

Upon consideration of the November 17, 2011 order expediting briefing on the merits of this appeal, the motions to consolidate this appeal with forthcoming appeals, the motion for leave to file a corrected opening brief, the motion for leave to file public and confidential versions of its reply in support of its motion to stay the injunction, and the motions to amend the official caption to add Watson Pharma, Inc.,

IT IS ORDERED THAT:
(1) Oral argument for the merits of the appeal is scheduled to be held at 10 a.m., January 24, 2012, in Courtroom 201. The parties shall notify the clerk in writing of the name of the counsel who will present oral argument no later than January 9, 2012.
(2) The motions to consolidate will be granted and the official caption will be amended to add the appeal numbers from the district court's November 23, 2011 order denying their motion to dissolve the injunction and the district court's December 2, 2011 order denying their emergency motion for relief from the injunction, when those new appeals are docketed by this court.
(3) The motions to reform the caption are granted. Watson Pharma, Inc. is added to the caption. The revised official caption is reflected above.

http://www.leagle.com/xmlResult.aspx?xmldoc=In%20FCO%2020111206163.xml&docbase=CSLWAR3-2007-CURR



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist